INCR vs. ALT, SIGA, YMAB, PEPG, TRDA, ATXS, CDMO, LRMR, CYRX, and CMPS
Should you be buying InterCure stock or one of its competitors? The main competitors of InterCure include Altimmune (ALT), SIGA Technologies (SIGA), Y-mAbs Therapeutics (YMAB), PepGen (PEPG), Entrada Therapeutics (TRDA), Astria Therapeutics (ATXS), Avid Bioservices (CDMO), Larimar Therapeutics (LRMR), Cryoport (CYRX), and COMPASS Pathways (CMPS). These companies are all part of the "pharmaceutical preparations" industry.
Altimmune (NASDAQ:ALT) and InterCure (NASDAQ:INCR) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, media sentiment, profitability, risk, institutional ownership, community ranking and valuation.
InterCure has higher revenue and earnings than Altimmune. Altimmune is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.
Altimmune received 46 more outperform votes than InterCure when rated by MarketBeat users. However, 100.00% of users gave InterCure an outperform vote while only 70.00% of users gave Altimmune an outperform vote.
Altimmune currently has a consensus target price of $17.25, suggesting a potential upside of 129.69%. Given InterCure's higher probable upside, research analysts clearly believe Altimmune is more favorable than InterCure.
In the previous week, Altimmune had 13 more articles in the media than InterCure. MarketBeat recorded 15 mentions for Altimmune and 2 mentions for InterCure. Altimmune's average media sentiment score of 0.43 beat InterCure's score of 0.28 indicating that InterCure is being referred to more favorably in the news media.
Altimmune has a beta of 0.22, indicating that its stock price is 78% less volatile than the S&P 500. Comparatively, InterCure has a beta of 1.63, indicating that its stock price is 63% more volatile than the S&P 500.
InterCure has a net margin of 0.00% compared to InterCure's net margin of -22,645.37%. Altimmune's return on equity of 0.00% beat InterCure's return on equity.
78.1% of Altimmune shares are owned by institutional investors. Comparatively, 8.3% of InterCure shares are owned by institutional investors. 4.1% of Altimmune shares are owned by company insiders. Comparatively, 0.2% of InterCure shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Summary
InterCure beats Altimmune on 10 of the 17 factors compared between the two stocks.
Get InterCure News Delivered to You Automatically
Sign up to receive the latest news and ratings for INCR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
InterCure Competitors List
Related Companies and Tools
